<DOC>
	<DOCNO>NCT00103389</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . PI-88 may stop growth non-small cell lung cancer block blood flow tumor . It may also help docetaxel work well make tumor cell sensitive drug . Giving docetaxel together PI-88 may kill tumor cell . It yet know whether give docetaxel together PI-88 effective docetaxel alone treat non-small cell lung cancer . PURPOSE : This randomized phase II trial study docetaxel PI-88 see well work give together compare docetaxel alone treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel With Without PI-88 Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare safety efficacy docetaxel v without PI-88 patient stage IIIB IV non-small cell lung cancer . Secondary - Determine efficacy marker docetaxel PI-88 patient . - Determine safety potential efficacy PI-88 alone maintenance therapy patient whose disease control docetaxel PI-88 combination therapy . - Determine safety potential efficacy PI-88 alone third-line therapy patient . OUTLINE : This open-label , randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 , 8 , 15 . - Arm II : Patients receive docetaxel arm I . Patients also receive PI-88 subcutaneously daily day 1-4 , 8-11 , 15-18 . In arm , treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients arm II stable respond disease 6 course may continue receive PI-88 alone maintenance therapy . Patients arm I progressive disease unacceptable toxicity completion 6 course may receive PI-88 alone third-line therapy . PROJECTED ACCRUAL : Approximately 100 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonsmall cell lung cancer Stage IIIB IV disease Eligible secondline docetaxel Disease progression completion prior firstline therapy comprise radiotherapy and/or platinumbased chemotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy At least 2 month Hematopoietic Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 WBC &gt; 3,000/mm^3 No history thrombotic thrombocytopenic purpura platelet disease Hepatic Bilirubin normal ALT AST ≤ 2.5 time upper limit normal ( ULN ) ( 1.5 time ULN alkaline phosphatase &gt; 2.5 time ULN ) Alkaline phosphatase ≤ 5 time ULN ( unless bone metastasis present ) PT &lt; 1.5 time ULN Activated PTT normal Renal Creatinine clearance glomerular filtration rate &gt; 50mL/min Cardiovascular None follow within past 3 month : Myocardial infarction Stroke Congestive heart failure Immunologic No history immunemediated thrombocytopenia No evidence antiheparin antibodies No history allergy and/or hypersensitivity anticoagulant thrombolytic agent , especially heparin No history allergy polysorbate 80 No uncontrolled serious infection within past 4 week Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior docetaxel Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 3 month since prior radiotherapy &gt; 30 % marrowbearing bone Concurrent local palliative radiotherapy allow Surgery More 4 week since prior major surgery Other More 4 week since prior antineoplastic therapy More 2 week since prior concurrent heparin lowmolecular weight heparin More 4 week since prior investigational therapy No concurrent aspirin aspirincontaining medication except lowdose aspirin ( ≤ 100 mg/day ) No concurrent nonsteroidal antiinflammatory drug except cyclooxygenase2 inhibitor No concurrent warfarin warfarincontaining medication except lowdose warfarin ( ≤ 1 mg/day ) No concurrent antiplatelet drug , include follow : Abciximab Clopidogrel Dipyridamole Ticlopidine Tirofiban No concurrent drug may inhibit docetaxel metabolism , include follow : Cyclosporine Terfenadine Ketoconazole Erythromycin Troleandomycin No concurrent investigational drug No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>